| scholarly article | Q13442814 |
| P50 | author | Keith Flaherty | Q6384357 |
| Dirk Schadendorf | Q32649390 | ||
| Axel Hauschild | Q32649861 | ||
| Georgina V. Long | Q42947998 | ||
| Richard F. Kefford | Q46460242 | ||
| Patrick Hwu | Q89392895 | ||
| Vicki Goodman | Q117251019 | ||
| Jeffrey J Legos | Q117251020 | ||
| P2093 | author name string | Robert Gagnon | |
| Anne-Marie Martin | |||
| Michelle Casey | |||
| Ademi Santiago-Walker | |||
| Anne O'Hagan | |||
| Jennifer Carver | |||
| Jolly Mazumdar | |||
| Patricia Haney | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 567-574 | |
| P577 | publication date | 2015-10-07 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. | |
| P478 | volume | 22 |
| Q91646745 | Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma |
| Q58113203 | Cell-free DNA in cancer: current insights |
| Q90645875 | Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma |
| Q39534880 | Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma |
| Q26745985 | Circulating biomarkers to monitor cancer progression and treatment |
| Q52601844 | Circulating cell-free DNA for non-invasive cancer management. |
| Q89496328 | Circulating tumor DNA analysis in the era of precision oncology |
| Q58704645 | Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors |
| Q48522100 | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| Q38780043 | Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. |
| Q57143867 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy |
| Q49464812 | Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma |
| Q49112520 | Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. |
| Q100455159 | Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i |
| Q55186392 | Concerning the article by Louveau et al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor". |
| Q92206685 | Considering adjuvant therapy for stage II melanoma |
| Q55536917 | Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. |
| Q52658584 | Cutaneous melanoma: From pathogenesis to therapy (Review). |
| Q36378903 | Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer |
| Q64080463 | Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples |
| Q89749356 | EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients |
| Q38661826 | Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report |
| Q58757488 | From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting |
| Q47563363 | Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System? |
| Q48527971 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers |
| Q39149201 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. |
| Q38700529 | Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients |
| Q57471881 | Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma |
| Q58781162 | MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With Mutation Detected in Circulating-Free DNA |
| Q47227422 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells |
| Q39208242 | Molecular genetic and immunotherapeutic targets in metastatic melanoma |
| Q47392574 | Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine |
| Q59799469 | Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients |
| Q38376723 | Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction |
| Q38376337 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers |
| Q90569462 | Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review |
| Q96953882 | Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations |
| Q58079189 | Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies |
| Q39292740 | Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. |
| Q93271158 | Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma |
| Q39408199 | Platelets, circulating tumor cells, and the circulome. |
| Q92297174 | Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients |
| Q36815383 | Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors |
| Q55016615 | Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. |
| Q43274590 | Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma |
| Q38856722 | Targeted agents and immunotherapies: optimizing outcomes in melanoma |
| Q88319624 | Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification |
| Q37244501 | Technological advances in precision medicine and drug development |
| Q97646131 | The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape |
| Q48143437 | The Value of Cell-free DNA for Molecular Pathology |
| Q52686846 | The brim of uncertainty in adjuvant treatment of melanoma. |
| Q64078507 | The emerging role of cell-free DNA as a molecular marker for cancer management |
| Q92378915 | Tumour biomarkers-Tracing the molecular function and clinical implication |
| Q56890934 | Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs |
| Q93040523 | Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation |
| Q49298466 | Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies |
| Q40460053 | Using circulating cell-free DNA to monitor personalized cancer therapy. |
| Q48233659 | Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. |
Search more.